Posting of 2021 Annual Report and Notice of AGM


C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

15 December 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that it has today published and posted to shareholders the Annual Report and Accounts for the year ended 31 July 2021 and Notice of the Annual General Meeting (“AGM”) which will be held at Panmure Gordon, One New Change, London, EC4M 9AF, on 18 January 2022 at 2.00 p.m. (GMT).

The Annual Report and Accounts and notice of AGM are also available to view on, and download from, the Company’s website at

C4X Discovery Holdings plc

Mo Noonan, Communications+44 (0)7876 444 977

Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)

Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700

C4X Discovery (“C4XD”) is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.